Serevent Diskhaler (salmeterol dry-powder inhaler) / GSK - LARVOL DELTA

GSK announces cap of $35 per month on U.S. patient out-of-pocket costs for its entire portfolio of asthma and COPD inhalers (GSK Press Release) - GSK today announced it will cap out-of-pocket costs for eligible patients at no more than $35 per month for all of its asthma and chronic obstructive pulmonary disease (COPD) medicines...The out-of-pocket price cap will provide a significant benefit to patients taking these medicines whose monthly costs currently exceed $35....The program is wide reaching and will be implemented no later than January 1, 2025. The medicines in scope are: Advair Diskus (fluticasone propionate and salmeterol inhalation powder). Advair HFA (fluticasone propionate and salmeterol inhalation aerosol). Anoro Ellipta (umeclidinium and vilanterol inhalation powder). Arnuity Ellipta (fluticasone furoate inhalation powder). Breo Ellipta (fluticasone furoate and vilanterol inhalation powder). Incruse Ellipta (umeclidinium inhalation powder). Serevent Diskus (salmeterol xinafoate inhalation powder). Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol...

Pricing • Asthma • Chronic Obstructive Pulmonary Disease

"@GSKUS Do you have a recycling program for empty Serevent Diskus canisters?" (@DrLeslieEvelo)